Xbrane Biopharma AB (XBRANE) — Net Asset Quality Index
Xbrane Biopharma AB (XBRANE) has a Net Asset Quality Index of 82.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Skr670.76 Million minus total liabilities of Skr120.60 Million yields net assets of Skr550.16 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Xbrane Biopharma AB (XBRANE) liquidity interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xbrane Biopharma AB Net Asset Quality Index Over Time (2012–2025)
This chart shows how Xbrane Biopharma AB's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 82.0%, representing net assets of Skr550.16 Million against total assets of Skr670.76 Million SEK. Explore XBRANE cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Xbrane Biopharma AB market cap and net worth.
| Year | Quality Index | Net Assets (SEK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.5% | Skr560.65 Million | Skr671.62 Million | Skr110.97 Million | ▲ +58.7 pp |
| 2024 | 24.8% | Skr208.54 Million | Skr842.43 Million | Skr633.89 Million | ▼ -1.5 pp |
| 2023 | 26.2% | Skr171.34 Million | Skr653.51 Million | Skr482.17 Million | ▼ -35.3 pp |
| 2022 | 61.5% | Skr424.89 Million | Skr690.51 Million | Skr265.63 Million | ▼ -1.2 pp |
| 2021 | 62.7% | Skr431.74 Million | Skr688.43 Million | Skr256.69 Million | ▲ +7.1 pp |
| 2020 | 55.6% | Skr257.71 Million | Skr463.76 Million | Skr206.06 Million | ▲ +1.2 pp |
| 2019 | 54.4% | Skr184.32 Million | Skr338.94 Million | Skr154.62 Million | ▲ +21.5 pp |
| 2018 | 32.8% | Skr83.07 Million | Skr252.88 Million | Skr169.81 Million | ▼ -46.8 pp |
| 2017 | 79.7% | Skr88.41 Million | Skr110.96 Million | Skr22.55 Million | ▼ -11.2 pp |
| 2016 | 90.8% | Skr107.30 Million | Skr118.11 Million | Skr10.81 Million | ▲ +27.8 pp |
| 2015 | 63.1% | Skr47.51 Million | Skr75.33 Million | Skr27.82 Million | ▼ -31.1 pp |
| 2014 | 94.2% | Skr6.30 Million | Skr6.69 Million | Skr390.70K | ▼ -0.3 pp |
| 2013 | 94.5% | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +81.1 pp |
| 2012 | 13.4% | Skr88.11K | Skr657.01K | Skr568.90K | — |